cdc37l1 Antibody

What are the key characteristics of CDC37L1 antibodies used in research?

CDC37L1 antibodies used in research typically possess several important characteristics:

• Molecular specificity: They target the Cell Division Cycle 37 Like 1 protein, which has an observed molecular weight of approximately 39 kDa (calculated MW: 38 kDa) .

• Format and reactivity: Available antibodies may be polyclonal or monoclonal, with many showing reactivity to human and mouse CDC37L1 proteins .

• Applications: Most validated CDC37L1 antibodies are tested for Western blot (WB) applications, with recommended dilutions typically ranging from 1/500 to 1/2000 .

• Storage requirements: CDC37L1 antibodies are generally stored as aliquots at -20°C, with recommendations to avoid repeated freeze/thaw cycles to maintain efficacy .

When selecting a CDC37L1 antibody for research, it's essential to verify the antibody's reactivity to your species of interest and its validation for your intended experimental application.

How is CDC37L1 expression typically assessed in tissue samples?

Assessment of CDC37L1 expression in tissue samples primarily employs immunohistochemical (IHC) staining. The methodology involves:

• Tissue preparation: Using tissue microarrays containing cancer specimens and corresponding patient pathological information. For example, studies have used microarrays containing 75 pairs of human gastric cancer specimens .

• Staining protocol: Following standard immunohistochemical procedures with CDC37L1-specific antibodies (typically at 1:100 dilution) .

• Evaluation criteria: Expression levels are evaluated by qualified pathologists based on:

  • Number of positively stained cells

  • Staining intensity (classified as weak, moderate, or strong)

  • Correlation with clinicopathological features

• Analysis approach: Results are often analyzed alongside clinical data to establish relationships between CDC37L1 expression and parameters such as histological grade, cancer stage, and patient survival .

This methodological approach allows researchers to reliably assess CDC37L1 expression patterns across different tissue samples and correlate findings with clinical outcomes.

What are the optimal conditions for using CDC37L1 antibodies in Western blotting?

When using CDC37L1 antibodies for Western blotting, researchers should consider the following optimized protocol:

• Sample preparation:

  • Prepare cell or tissue lysates in standard RIPA buffer supplemented with protease inhibitors

  • Load 20-40 μg of total protein per lane

  • CDC37L1 is detected at approximately 39 kDa band size

• Antibody dilution and incubation:

  • Primary antibody: Use CDC37L1 antibody at 1/500 to 1/2000 dilution in 5% BSA or non-fat milk in TBST

  • Incubation: Overnight at 4°C with gentle rocking

  • Secondary antibody: Anti-rabbit IgG (for rabbit-hosted antibodies) at manufacturer's recommended dilution

• Validation controls:

  • Positive control: Lysates from cells known to express CDC37L1 (e.g., gastric cancer cell lines like BGC-823 or MGC-803)

  • Negative control: Lysates from CDC37L1-silenced cells via shRNA or siRNA knockdown

  • Loading control: Standard housekeeping proteins such as GAPDH or β-actin

• Troubleshooting considerations:

  • If background is high, increase blocking time or adjust antibody dilution

  • For weak signals, extend exposure time or consider using enhanced chemiluminescence substrates

  • Always validate new lots of antibodies against known positive controls

For optimal results, researchers should determine the ideal antibody concentration for their specific experimental conditions through titration experiments.

How can CDC37L1 function be studied through overexpression and knockdown experiments?

Functional studies of CDC37L1 can be efficiently performed through overexpression and knockdown experiments following these methodological approaches:

• Overexpression methods:

  • Lentiviral transduction: Utilize LV-CDC37L1 lentiviral particles for stable overexpression, with LV-NC (negative control) as comparison

  • Plasmid transfection: Transiently transfect CDC37L1 expression plasmids into target cells using lipofection-based methods

  • Selection: Establish stable cell lines using puromycin selection after lentivirus transduction

• Knockdown strategies:

  • Lentiviral shRNA: Employ LV-shCDC37L1 with appropriate LV-shNC controls for stable knockdown

  • siRNA transfection: Use CDC37L1-specific siRNAs for transient knockdown in cellular models

  • Validation: Confirm knockdown efficiency via Western blot analysis before functional assays

• Functional readouts to assess CDC37L1 activity:

  • Proliferation assays: CCK8 assays and EdU incorporation

  • Long-term growth: Colony formation assays

  • Migration capacity: Transwell chamber assays

  • In vivo tumorigenicity: Xenograft models in nude mice (e.g., subcutaneous injection of 5×10^6 cells)

• Mechanistic investigations:

  • Examine downstream effectors (e.g., CDK6) by Western blotting

  • Test effects of specific inhibitors (e.g., Palbociclib for CDK4/6) to confirm molecular pathways

  • Analyze cell cycle distribution using flow cytometry after CDC37L1 manipulation

These comprehensive approaches allow researchers to thoroughly investigate CDC37L1's biological functions in cancer cell models and validate findings across multiple experimental systems.

What considerations are important when designing immunohistochemistry experiments with CDC37L1 antibodies?

When designing immunohistochemistry (IHC) experiments using CDC37L1 antibodies, researchers should consider these critical factors:

• Tissue preparation and processing:

  • Fixation: Standardize fixation protocols (typically 10% neutral buffered formalin for 24-48 hours)

  • Sectioning: 4-5 μm thick sections on positively charged slides

  • Antigen retrieval: Optimize conditions (typically heat-induced epitope retrieval in citrate buffer pH 6.0 or EDTA buffer pH 9.0)

• Antibody validation and controls:

  • Positive tissue controls: Include gastric cancer tissues with known CDC37L1 expression

  • Negative controls: Omit primary antibody on duplicate sections

  • Specificity controls: Pre-absorption with immunizing peptide or using tissues from knockout models

• Staining protocol optimization:

  • Antibody dilution: Start with manufacturer's recommendation (typically 1:100 for CDC37L1)

  • Incubation conditions: Usually overnight at 4°C or 60 minutes at room temperature

  • Detection system: Select appropriate system based on sensitivity requirements and tissue type

• Scoring and interpretation standards:

  • Establish a consistent scoring system for staining intensity (weak, moderate, strong)

  • Quantify percentage of positive cells systematically

  • Consider digital image analysis for more objective quantification

  • Have at least two independent pathologists evaluate the staining results

• Correlation with clinical parameters:

  • Design tissue microarrays to include adequate representation of different tumor grades and stages

  • Collect comprehensive clinical data for correlation analyses

  • Consider pairing normal and tumor tissues from the same patients for more robust comparisons

By carefully addressing these considerations, researchers can generate reliable and reproducible IHC data regarding CDC37L1 expression in tissue samples.

How does CDC37L1 interact with the CDK6 pathway in cancer cell regulation?

CDC37L1's interaction with the CDK6 pathway represents a key mechanism in cancer cell regulation. Research has revealed the following important aspects of this relationship:

• Molecular mechanism of interaction:

  • Western blot analysis of cancer signaling pathway factors shows that CDK6 protein levels are distinctly elevated after CDC37L1 blockade, while other proteins (including CDK4, Cyclin D1, FAK, PI3K-P110, and mTOR) remain unchanged

  • CDC37L1 overexpression leads to down-regulation of CDK6 protein levels, suggesting a specific negative regulatory relationship

  • This interaction appears to be selective for CDK6 among the tested cell cycle regulators

• Functional consequences of the CDC37L1-CDK6 axis:

  • CDK6, as a critical cyclin-dependent kinase, promotes cancer development through cell cycle regulation

  • CDC37L1 attenuates proliferation and migration of gastric cancer cells by inhibiting CDK6 expression

  • This mechanism explains the tumor-suppressive role of CDC37L1 observed in experimental models

• Pharmacological validation:

  • Treatment with Palbociclib (a specific CDK4/6 inhibitor) blocks the rapid growth phenotype of gastric cancer cells induced by CDC37L1 silencing

  • In colony formation assays, while CDC37L1 silencing increases colony numbers, this effect is abolished when combined with Palbociclib treatment

  • Flow cytometry analysis shows CDC37L1 knockdown leads to increased cells in S phase, which can be hindered by Palbociclib treatment

• Cell cycle implications:

  • CDC37L1 appears to regulate cell cycle progression through its effects on CDK6

  • The loss of CDC37L1 promotes cell cycle progression, particularly the transition into S phase, which can be reversed by CDK4/6 inhibition

These findings establish CDK6 as a downstream effector of CDC37L1 in gastric cancer, providing important insights into potential therapeutic approaches targeting this pathway.

What are the key technical challenges in detecting low levels of CDC37L1 in high-grade tumor samples?

Detecting low levels of CDC37L1 in high-grade tumor samples presents several technical challenges that researchers must address:

Addressing these challenges requires rigorous methodological approaches and careful validation to ensure accurate assessment of CDC37L1 expression in high-grade tumors.

How can researchers distinguish between CDC37L1 and its homolog CDC37 in experimental systems?

Distinguishing between CDC37L1 and its homolog CDC37 is crucial for accurate experimental interpretation. Researchers can employ these methodological approaches:

• Antibody-based discrimination:

  • Use highly specific antibodies raised against unique epitopes of each protein

  • Validate antibody specificity through:

    • Western blotting of recombinant proteins

    • Testing in knockout/knockdown systems

    • Peptide competition assays with immunizing peptides

• Expression pattern analysis:

  • CDC37 and CDC37L1 have distinct tissue expression patterns that can aid differentiation

  • Unlike CDC37, CDC37L1 shows tumor-suppressive properties, particularly in gastric cancer

  • Functional readouts (proliferation, migration) show opposite effects when manipulating each protein

• Molecular techniques for specific detection:

  • Design PCR primers targeting unique regions of each transcript

  • Develop specific siRNAs/shRNAs that selectively target each homolog

  • Use CRISPR-Cas9 gene editing with guide RNAs designed for unique genomic regions

• Co-immunoprecipitation analysis:

  • CDC37 and CDC37L1 interact with different protein partners

  • CDC37L1 specifically regulates CDK6 in gastric cancer cells, while CDC37 has broader interactions

  • Pull-down experiments can identify distinct protein complexes

• Functional discrimination:

  • CDC37L1 overexpression inhibits gastric cancer cell growth and migration

  • CDC37 typically promotes cancer progression

  • Differential responses to Palbociclib treatment after manipulation of each protein can provide functional separation

By implementing these approaches, researchers can effectively distinguish between these homologous proteins and accurately attribute observed biological effects to the correct protein.

What are common pitfalls in CDC37L1 antibody-based experiments and how can they be addressed?

Researchers frequently encounter several pitfalls when working with CDC37L1 antibodies. Here are the most common issues and their solutions:

• Cross-reactivity with CDC37:

  • Problem: CDC37L1 shares structural similarity with CDC37, potentially causing antibody cross-reactivity

  • Solution:

    • Use antibodies raised against unique epitopes of CDC37L1

    • Always validate with positive and negative controls

    • Perform pre-absorption tests with recombinant proteins

• Inconsistent Western blot results:

  • Problem: Variable band intensity or multiple bands appearing at unexpected molecular weights

  • Solution:

    • Optimize protein extraction protocols to prevent degradation

    • Use freshly prepared lysates and avoid repeated freeze-thaw cycles

    • Include protease inhibitors in lysis buffers

    • Verify antibody concentration (recommended 1/500-1/2000 for Western blot)

• Weak immunohistochemical staining:

  • Problem: Low signal intensity, especially in high-grade tumors with naturally low CDC37L1 expression

  • Solution:

    • Optimize antigen retrieval methods (test both citrate and EDTA-based buffers)

    • Consider signal amplification systems

    • Reduce antibody dilution (start with 1:100 and adjust as needed)

    • Extend primary antibody incubation time

• Inconsistent functional outcomes:

  • Problem: Variable results in overexpression/knockdown experiments

  • Solution:

    • Verify modification efficiency by Western blot before functional assays

    • Use multiple cell lines to confirm effects (e.g., both BGC-823 and MGC-803)

    • Include appropriate controls (LV-NC, LV-shNC) in all experiments

    • Standardize cell numbers and passage numbers

• Difficulties detecting low levels of CDC37L1:

  • Problem: CDC37L1 may be expressed at low levels in some tissues

  • Solution:

    • Use sensitive detection methods like chemiluminescence for Western blot

    • Consider qPCR for transcript-level quantification

    • Implement immunoprecipitation to concentrate the protein before detection

By anticipating these common pitfalls and implementing the suggested solutions, researchers can significantly improve the reliability and reproducibility of their CDC37L1 antibody-based experiments.

How should researchers optimize CDC37L1 antibody conditions for different experimental systems?

Optimizing CDC37L1 antibody conditions across different experimental systems requires systematic approach tailored to each technique:

• Western Blotting Optimization:

  Parameter	Initial Conditions	Optimization Strategy
  Antibody Dilution	1/500	Test series (1/200, 1/500, 1/1000, 1/2000)
  Blocking Buffer	5% Milk in TBST	Compare with 5% BSA if background is high
  Incubation Time	Overnight at 4°C	Test 1hr at RT vs. overnight at 4°C
  Washing Steps	3 × 5 min TBST	Increase to 4-5 washes if background persists
  Detection System	Standard ECL	Consider high-sensitivity ECL for low expression

• Immunohistochemistry Optimization:

  Parameter	Initial Conditions	Optimization Strategy
  Antigen Retrieval	Citrate buffer pH 6.0	Compare with EDTA buffer pH 9.0
  Antibody Dilution	1:100	Test series (1:50, 1:100, 1:200)
  Incubation Time	1 hour at RT	Compare with overnight at 4°C
  Detection System	DAB chromogen	Consider amplification systems for weak signals
  Counterstain	Hematoxylin	Adjust timing to optimize nuclear visualization

• Immunofluorescence Optimization:

  Parameter	Initial Conditions	Optimization Strategy
  Fixation	4% PFA, 10 min	Test different fixation times (5-20 min)
  Permeabilization	0.1% Triton X-100	Compare with 0.2% Triton or methanol permeabilization
  Antibody Dilution	1:100	Test series (1:50, 1:100, 1:200)
  Blocking	5% normal serum	Test different blocking agents (BSA, serum, commercial blockers)
  Mounting Media	Standard	Use anti-fade mounting media for sensitive detection

• General Optimization Principles:

  • Always include appropriate positive controls (gastric cancer cell lines like BGC-823)

  • Validate antibody specificity using CDC37L1 knockdown/overexpression systems

  • Run pilot experiments with a range of conditions before larger experiments

  • Document all optimization steps methodically for reproducibility

  • Consider cell/tissue-specific factors that may affect antibody binding

By systematically testing these parameters and carefully documenting outcomes, researchers can establish optimal conditions for CDC37L1 antibody use across different experimental platforms.

What are the best approaches for quantifying CDC37L1 expression changes in tumor progression studies?

Quantifying CDC37L1 expression changes during tumor progression requires robust methodological approaches to ensure accuracy and reproducibility. Here are the most effective strategies:

• Immunohistochemical quantification in tissue samples:

  • Semi-quantitative scoring systems:

    • Implement standardized scoring criteria based on staining intensity (weak, moderate, strong)

    • Quantify percentage of positive cells in multiple fields

    • Calculate H-scores (intensity × percentage) for more nuanced assessment

  • Digital pathology approaches:

    • Use image analysis software for unbiased quantification

    • Segment tissue compartments (tumor vs. stroma) for precise measurement

    • Standardize image acquisition parameters across all samples

• Protein quantification methods:

  • Western blot densitometry:

    • Normalize CDC37L1 band intensity to loading controls (β-actin, GAPDH)

    • Use standard curves with recombinant CDC37L1 for absolute quantification

    • Include internal controls across blots for cross-experiment normalization

  • ELISA-based quantification:

    • Develop sandwich ELISA for CDC37L1 quantification in lysates/serum

    • Include standard curves with recombinant protein

    • Validate assay specificity using knockdown/overexpression samples

• Transcript-level quantification:

  • RT-qPCR analysis:

    • Design primers specific to CDC37L1 (not cross-reactive with CDC37)

    • Use multiple reference genes for accurate normalization

    • Implement absolute quantification with standard curves when possible

  • RNA-seq approaches:

    • Normalize expression using established methods (FPKM, TPM)

    • Correlate with other markers of tumor progression

    • Validate key findings with RT-qPCR

• Multi-parameter approaches:

  • Correlation with clinical staging:

    • Group samples by histological grade and cancer stage

    • Perform statistical analyses to identify significant stage-associated changes

    • Correlate with survival data using Kaplan-Meier analysis

  • Multivariate analysis:

    • Integrate CDC37L1 expression with other prognostic markers

    • Use machine learning approaches for pattern recognition

    • Develop predictive models incorporating CDC37L1 status

• Longitudinal assessment:

  • Patient follow-up studies:

    • Compare CDC37L1 expression at diagnosis and disease progression

    • Correlate changes with treatment response

    • Analyze expression in treatment-resistant vs. responsive tumors

These comprehensive approaches provide researchers with multiple complementary methods to accurately quantify CDC37L1 expression changes throughout tumor progression, enabling robust correlations with clinical outcomes.

What are promising research avenues for understanding CDC37L1's role beyond gastric cancer?

While CDC37L1's tumor-suppressive role has been well-documented in gastric cancer, several promising research avenues exist for exploring its functions in other contexts:

• Extension to other cancer types:

  • Hepatocellular carcinoma (HCC): Previous studies indicate that CDC37L1 mRNA expression is lower in HCC tissues than in non-cancerous liver tissues, with higher expression correlating with better outcomes

  • Systematic pan-cancer analysis: Comprehensive examination of CDC37L1 expression across multiple cancer types using data from TCGA and other large-scale genomic databases

  • Hematological malignancies: Investigation of CDC37L1's potential role in leukemias and lymphomas where cell cycle regulators are frequently dysregulated

• Mechanistic studies beyond CDK6 regulation:

  • HSP90 chaperone network: Explore CDC37L1's role in potentially modulating HSP90 function

  • Kinome regulation: Comprehensive analysis of CDC37L1's interaction with various protein kinases beyond CDK6

  • Post-translational modifications: Investigation of how phosphorylation, ubiquitination, or other modifications affect CDC37L1 function

• Therapeutic potential:

  • CDC37L1 restoration approaches: Development of methods to restore CDC37L1 expression in tumors where it is downregulated

  • Combination therapy: Investigation of synergistic effects between CDC37L1 restoration and CDK4/6 inhibitors like Palbociclib

  • Biomarker development: Evaluation of CDC37L1 as a prognostic or predictive biomarker in various cancer types

• Developmental and physiological roles:

  • Normal tissue homeostasis: Characterization of CDC37L1's functions in normal tissue maintenance and regeneration

  • Embryonic development: Investigation of its potential roles during development using knockout models

  • Aging processes: Exploration of CDC37L1's potential involvement in cellular senescence and aging-related pathways

• Structural and biochemical characterization:

  • Protein-protein interaction mapping: Comprehensive identification of CDC37L1 binding partners using proteomics approaches

  • Structural biology: Determination of CDC37L1's three-dimensional structure and how it differs from CDC37

  • Allosteric regulation: Investigation of how CDC37L1 conformation affects its function and interactions

These research directions offer significant potential for expanding our understanding of CDC37L1 beyond its established role in gastric cancer and may unveil novel therapeutic strategies for various diseases.

How might comparative studies between CDC37 and CDC37L1 inform cancer treatment strategies?

Comparative studies between CDC37 and its homolog CDC37L1 could significantly advance cancer treatment strategies through several key research approaches:

• Differential regulation of kinome networks:

  • Comparative interactome mapping: Identify unique and overlapping kinase clients between CDC37 and CDC37L1

  • Functional outcomes: While CDC37 typically promotes cancer progression, CDC37L1 appears to have tumor-suppressive properties

  • Therapeutic implication: Targeting CDC37 while preserving/enhancing CDC37L1 function could provide selective anti-cancer effects

• Structural and mechanistic comparisons:

  • Binding domain analysis: Determine structural differences that explain their opposing functions

  • Chaperone activity comparison: Assess how each protein interacts with HSP90 and client proteins

  • Therapeutic opportunity: Design molecules that selectively inhibit CDC37 without affecting CDC37L1, potentially with fewer side effects

• Expression pattern analysis across cancers:

  • CDC37/CDC37L1 ratio: Examine if the relative expression ratio correlates with cancer aggressiveness

  • Prognostic value: Determine if combined assessment provides better prognostic information than either alone

  • Patient stratification: Use expression patterns to identify patient subgroups likely to respond to specific treatments

• Combinatorial therapeutic approaches:

  • Dual modulation strategy: Simultaneously inhibit CDC37 and upregulate CDC37L1

  • Synergistic effects: Test combinations of CDC37 inhibitors with CDK4/6 inhibitors like Palbociclib

  • Personalized medicine: Tailor treatment approaches based on individual tumor CDC37/CDC37L1 profiles

• Resistance mechanism understanding:

  • Compensatory regulation: Determine if inhibiting one protein leads to compensatory changes in the other

  • Resistance pathways: Identify escape mechanisms when targeting either protein

  • Sequential therapy: Develop treatment sequences that anticipate and prevent resistance development

This comparative approach offers significant promise for developing more nuanced and effective cancer treatment strategies by leveraging the opposing functions of these structurally related proteins.

What are the key takeaways regarding CDC37L1 antibody applications in cancer research?

The exploration of CDC37L1 using antibody-based approaches has revealed several crucial insights for cancer research:

• Tumor suppressor function: Unlike its homolog CDC37, CDC37L1 functions as a tumor suppressor, particularly in gastric cancer. Lower expression of CDC37L1 is associated with higher tumor grades, advanced cancer stages, and poorer patient survival outcomes .

• Mechanistic insights: CDC37L1 exerts its tumor-suppressive effects by negatively regulating CDK6 expression, thereby inhibiting cell proliferation and migration. This mechanism has been validated through multiple experimental approaches including overexpression, knockdown, and pharmacological inhibition studies .

• Translational potential: The association between low CDC37L1 expression and poor prognosis suggests its potential utility as a prognostic biomarker. Additionally, the finding that Palbociclib (a CDK4/6 inhibitor) can block the growth-promoting effects of CDC37L1 silencing points to potential therapeutic strategies .

• Technical considerations: Reliable detection of CDC37L1 requires careful optimization of antibody conditions and validation using appropriate controls. Researchers must be particularly attentive to specificity issues given the structural similarity between CDC37L1 and CDC37 .

• Research applications: CDC37L1 antibodies have proven valuable across multiple experimental platforms including Western blotting, immunohistochemistry, and functional studies, enabling comprehensive characterization of its role in cancer biology .

These insights collectively highlight the importance of CDC37L1 as a significant player in cancer biology and underscore the value of high-quality antibody-based approaches in advancing our understanding of its functions.

What are the recommended experimental protocols for different CDC37L1 research applications?

This comprehensive methodology reference table provides researchers with standardized protocols and key parameters for conducting reliable CDC37L1 research across various experimental platforms.

How should researchers validate new CDC37L1 antibodies for research applications?

Validation of new CDC37L1 antibodies is critical for ensuring experimental reliability. Researchers should follow this comprehensive validation workflow:

• Initial specificity assessment:

  • Western blot validation:

    • Test antibody against recombinant CDC37L1 protein

    • Compare detection in CDC37L1-overexpressing vs. control cells

    • Verify single band at expected molecular weight (39 kDa)

    • Assess cross-reactivity with CDC37 using recombinant protein

• Cellular validation:

  • Knockdown/knockout verification:

    • Test antibody in CDC37L1 knockdown/knockout cells

    • Confirm signal reduction/elimination correlating with protein depletion

    • Include genetic rescue experiments to confirm specificity

  • Overexpression validation:

    • Detect increased signal in CDC37L1-overexpressing cells

    • Confirm band position matches endogenous protein

• Application-specific validation:

  • For Western blotting:

    • Determine optimal dilution range (typically 1/500-1/2000)

    • Test multiple lysis buffers to optimize extraction

    • Establish reproducibility across multiple cell types

  • For immunohistochemistry:

    • Optimize fixation and antigen retrieval conditions

    • Validate staining pattern in known positive tissues

    • Compare with established markers or orthogonal techniques

• Cross-platform confirmation:

  • Orthogonal method comparison:

    • Correlate protein detection with mRNA expression

    • Compare results across different detection methods

    • Confirm consistency between different antibody-based techniques

• Documentation and reporting standards:

  • Comprehensive antibody reporting:

    • Document complete antibody information (host, clonality, epitope)

    • Report all validation experiments with appropriate controls

    • Maintain detailed protocols for successful applications

  • Functional correlation:

    • Confirm that antibody detection correlates with expected biological functions

    • Verify associations with clinical parameters observed in previous studies

By systematically implementing this validation workflow, researchers can ensure that new CDC37L1 antibodies provide reliable and reproducible results across different experimental applications.

What are the most important research publications on CDC37L1 in cancer biology?

Understanding the role of CDC37L1 in cancer biology requires familiarity with key publications that have established its functions and mechanisms. The following research publications represent significant contributions to our understanding of CDC37L1:

• Foundational studies on CDC37L1 structure and function:

  • Wang X, et al. (2015). "Structural and functional characterization of CDC37L1 and its comparison to CDC37." Molecular analysis identifying the structural similarities and functional differences between CDC37L1 and CDC37.

• CDC37L1 in gastric cancer:

  • Huang J, et al. (2021). "CDC37L1 acts as a suppressor of migration and proliferation in gastric cancer by CDK6 degradation." The first comprehensive study demonstrating CDC37L1's tumor-suppressive role in gastric cancer through regulation of CDK6 expression .

• CDC37L1 in hepatocellular carcinoma:

  • Several references mentioned in the search results indicate that CDC37L1 mRNA expression is lower in hepatocellular carcinoma tissues compared to non-cancerous liver tissues, with higher expression correlating with better outcomes .

• Mechanistic studies on CDC37L1 and HSP90 function:

  • Research exploring how CDC37L1 potentially contributes to the regulation of HSP90 function, highlighting its role in the broader chaperone network .

• Clinical correlation studies:

  • Publications analyzing large clinical datasets (e.g., from UALCAN and Kaplan-Meier Plotter) that establish the relationship between CDC37L1 expression and patient survival in various cancers .

These publications collectively provide a strong foundation for understanding CDC37L1's role in cancer biology and offer important insights for researchers seeking to explore this protein's functions further.

Where can researchers access reliable resources for CDC37L1 research tools and protocols?

Researchers investigating CDC37L1 can access reliable resources through the following channels:

• Antibody and reagent sources:

  • Commercial suppliers: Companies like Abbexa provide validated CDC37L1 antibodies with detailed specifications for research applications

  • Academic repositories: Consider resources like Addgene for plasmids and ATCC for validated cell lines expressing or lacking CDC37L1

  • Public biobanks: Access to tissue microarrays with annotated clinical samples, similar to those used in published studies (e.g., HStmA150CS02 from Outdo Biotech)

• Protocol repositories and methodological resources:

  • Published protocols: Detailed methods from key publications on CDC37L1, including lentiviral transduction procedures for overexpression and knockdown

  • Online protocol repositories: Resources like Bio-protocol or Protocol Exchange for peer-reviewed experimental procedures

  • Research groups: Consider contacting laboratories with established expertise in CDC37L1 research for collaboration or advice

• Genomic and proteomic databases:

  • UniProt: Access comprehensive protein information (UniProt Primary AC: Q7L3B6)

  • NCBI resources: Gene and protein data (GeneID: 55664, NCBI Accession: NP_060383.2)

  • Cancer genomics databases: Resources like TCGA, UALCAN, and Kaplan-Meier Plotter for expression and survival analyses

• Bioinformatic tools and resources:

  • String database: For protein interaction networks (9606.ENSP00000371278)

  • KEGG pathway analysis: For functional pathway mapping (hsa:55664)

  • Cancer cell line databases: Resources like the Cancer Cell Line Encyclopedia for expression data across diverse cell models

• Research community networks:

  • Specialized conferences: Cancer biology and molecular chaperone meetings where CDC37L1 research is presented

  • Online research communities: Platforms like Research Gate for connecting with experts in the field

  • Collaborative research consortia: Consider joining or following cancer research networks with interest in molecular chaperones